Wednesday, January 4, 2017

BRIEF-U.S. FDA approves supplemental New Drug Applications for three Type 2 diabetes medicines

* U.S. FDA approves supplemental new drug applications to

include landmark data in product labels for synjardy

(empagliflozin/metformin hydrochloride), synjardy xr

(empagliflozin/metformin...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)